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Abstract
Objectives: Publication bias may affect the validity of evidence based medical decisions. The aim of this study is to assess
whether research outcomes affect the dissemination of clinical trial findings, in terms of rate, time to publication, and
impact factor of journal publications.
Methods and Findings: All drug-evaluating clinical trials submitted to and approved by a general hospital ethics committee
between 1997 and 2004 were prospectively followed to analyze their fate and publication. Published articles were identified
by searching Pubmed and other electronic databases. Clinical study final reports submitted to the ethics committee, final
reports synopses available online and meeting abstracts were also considered as sources of study results. Study outcomes
were classified as positive (when statistical significance favoring experimental drug was achieved), negative (when no
statistical significance was achieved or it favored control drug) and descriptive (for non-controlled studies). Time to
publication was defined as time from study closure to publication. A survival analysis was performed using a Cox regression
model to analyze time to publication. Journal impact factors of identified publications were recorded. Publication rate was
48?4% (380/785). Study results were identified for 68?9% of all completed clinical trials (541/785). Publication rate was 84?9%
(180/212) for studies with results classified as positive and 68?9% (128/186) for studies with results classified as negative
(p,0?001). Median time to publication was 2?09 years (IC95 1?61–2?56) for studies with results classified as positive and 3?21
years (IC95 2?69–3?70) for studies with results classified as negative (hazard ratio 1?99 (IC95 1?55–2?55). No differences were
found in publication impact factor between positive (median 6?308, interquartile range: 3?141–28?409) and negative result
studies (median 8?266, interquartile range: 4?135–17?157).
Conclusions: Clinical trials with positive outcomes have significantly higher rates and shorter times to publication than
those with negative results. However, no differences have been found in terms of impact factor.
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Background
Evidence-based medical decisions rely on the absence of bias in
the available published results. When the publication or not of a
particular study is determined by its outcomes or statistical
significance, the derived bias is unacceptable, since it results in an
exaggeration of the positive effects of a given treatment [1], [2].
Relevance of publication bias, in any of its manifestations, is
undoubtedly more serious when it relates to clinical trials involving
treatments in more advance phases of development, newly
approved drugs, or new indications for registered drugs, since it
may directly result in the use of less cost-effective, ineffective, or
even harmful interventions in clinical practice [1].
Efforts have been made to prevent and reduce publication bias,
including prospective registration of clinical trials [3], [4],
publication of results in public databases [5] or in sponsor websites
[6], and journal editors’ initiatives to promote trial registration [7].
However, a single universal tool to provide access to all clinical
trial results, regardless of their outcomes, is not currently available.
Previous research has documented the existence of lower
publication rates [8–12] and delay of publication [9], [13] in
studies with negative outcomes in comparison with studies with
positive outcomes. However, to our knowledge, no previous
studies have assessed publication bias in a large cohort of drug-
related clinical trials with known results, both positive and
negative.
Direction and strength of outcomes might also affect the
availability and extent of dissemination of study results as
measured by article impact factor. Few studies have assessed the
effect of study outcomes on impact factors, showing a tendency to
publish studies with positive results in high impact factor journals
[14], [15].
The aim of this study was to assess whether study outcomes
affect the dissemination of clinical trials findings, in terms of rate,
time to publication, and journal impact factor, in a cohort of
clinical trials with known results, publically available or not.
Furthermore, to evaluate the extent of publication bias in trials
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with a greater relevance on clinical practice, two subpopulation
analyses were performed, with phase 3 and 4 clinical trials, and
with trials in which conditions of use of experimental drugs had
been approved, before or after trial completion.
Methods
Source Data
All drug-evaluating clinical trials submitted to and approved by
the Ethics Committee (EC) of Hospital Vall d’Hebron in
Barcelona, Spain, between 1997 and 2004 were prospectively
followed to analyze their fate, results if available, and subsequent
publication. The following information was recorded: experimen-
tal drug name, medical condition, name and specialty of principal
investigator, main outcome, sample size, type of sponsor (industry
or no industry), phase of study, study design and dates of EC
approval, trial initiation and closure. Conditions of use of
experimental drugs were classified as approved or off label,
according to label information at the time of trial submission.
Current status of the trial was recorded at the time of database
closure (February 2010), categorized as not initiated, completed,
prematurely terminated, or ongoing. Final reports submitted to the
EC by the sponsor were also prospectively collected and filed for
ulterior analysis of results.
Study Results Search Strategy
Completed and prematurely terminated studies were classified
as published when at least one article was identified in peer
reviewed literature. Other sources of results, if found, were also
recorded: meeting abstracts, online final report synopses, and final
reports submitted by the sponsor to the EC.
We searched clinicaltrials.gov site to identify registered trials
and study publications, if mentioned, using drug name, medical
condition, sponsor identification and protocol number as key-
words. Additionally, literature searches were performed to identify
trial publications in the following databases of biomedical journals:
Pubmed, ISI web of knowledge and Cochrane Library Plus.
Keywords used in the search were drug name, medical condition,
sponsor name, principal investigator, and clinicaltrials.gov iden-
tification number, when available. If no hits were found in the first
strategy, a second search was performed, using only drug name
and medical condition as keywords. We also reviewed Spanish
language databases, Indice Me´dico Espan˜ol and the Spanish
Ministry of Education doctoral thesis database (TESEO) for
additional publications.
Criteria used to match identified publications to trials were
classified as fixed, which should be included in the publication
according to CONSORT guidelines [16], and optional, when
their inclusion in the article was per author decision. Fixed criteria
included identification of tested drugs (dosage and schedules),
study population (inclusion criteria and medical condition), sample
size, main outcome, statistical analysis and sponsor or funding
source. Optional criteria were protocol number or clinicaltrials.-
gov identification, and presence of the hospital and principal
investigator name in the list of participants.
We also checked sponsor websites and the online database
www.clinicalstudyresults.org to locate study final report synopses,
using drug name, medical condition, protocol number, and
clinicaltrials.gov identification number, when available, as key-
words.
Last search was performed during March 2010.
The following information was collected for identified publica-
tions: date of publication, journal name, and journal impact factor,
according to the 2008 list of journal impact factors [17].
Classification of Study Outcomes
For each trial, identified result sources were recorded and
quantified.
Results were classified as: 1) complete, 2) partial, when analysis
of results was preliminary or incomplete, or 3) not available, when
although the source of results was identified, it was not possible to
access the full text information.
For classification of results, we searched for significance on the
main outcome as defined in the original study protocol. When no
clear single main outcome was defined on the protocol, i.e.
multiple variables or multi-arm studies, the trial was considered
positive if any major outcome reached statistical significance
favoring the experimental group. When the only source of study
results was meeting abstract or journal publication, and the main
outcome was different than that defined on the protocol, the
outcome chosen to classify study results was that defined as main
outcome in the publication.
Study main outcomes were thus classified: as 1) positive (when
statistical significance favoring experimental drug was achieved,
p,0?05), 2) negative (when no statistical significance was achieved
or it favored control drug), and 3) descriptive (for non-controlled
studies). For trials designed as equivalence or noninferiority
studies, results were classified as positive when no significant
differences were found between the comparison treatment groups,
and as negative when they failed to prove the equivalence or
noninferiority criteria as defined by the study design.
Post-trial Drug Registration
Labels of experimental drugs were searched in the European
Medicine Agency (EMA) database in order to check whether
conditions of use had been approved in the European Union upon
trial completion. Last search was performed in March 2010.
Statistical Analysis
Descriptive analysis was performed for all variables. For
continuous variables, mean, median interquartile range, standard
deviation, and confidence intervals were calculated. Tables of
frequencies were elaborated for categorical variables.
Publication rates were compared with the use of the chi-square
test and Fisher’s exact test.
The Kaplan Meier method was used to analyze time to
publication. The influence of outcomes –positive, negative, and
descriptive- was evaluated with the use of the log-rank test. Hazard
ratios and confidence intervals were calculated on the basis of a
Cox regression model. Trial characteristics included in the analysis
were sponsorship type (industry or non-industry), phase of
development (1/2 or 3/4), sample size (categorized in four groups:
less than 100 subjects, 100 to 500 subjects, 500 to 1000 subjects,
and more than 1000 subjects), and medical specialty.
Differences on impact factor were studied through nonpara-
metric tests (U Mann Whitney or Kruskal Wallis) since the
variable did not follow normal distribution.
Primary analysis or rate and time to publication was performed
with the total population of completed trials. Secondary analyses
were also performed with the phase 3/4 completed trial
subpopulation and with the population of completed trials with
drugs whose conditions of use were already approved or had been
approved by regulatory authorities after trial completion.
Primary analysis of impact factor was performed with the total
population of published trials, and secondary analysis were
performed with phase 3/4 published trials and published trials
whose conditions of use were already approved or had been
approved by regulatory authorities after trials completion.
Impact Factor of Clinical Trial Publications
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Software used for statistical analysis was SPSS version 16.0
(SPSS Inc, Chicago, IL).
Results
During the study, 1054 drug-related clinical trials were
submitted to the Ethics Committee (EC). Ninety four were not
approved by the EC and 15 corresponded to duplicate submis-
sions. The remaining 945 clinical trials were included in the
analysis. Of these, 117 were never initiated and 43 were still
ongoing by the end of February 2010. Of the remaining 785
studies, 677 were completed according to protocol, while 108 were
prematurely terminated (figure 1). Two hundred and fifty nine of
all 945 evaluated trials (27?4%) were registered on clinicaltrials.-
gov.
Descriptive Analysis
Characteristics of the 785 finished studies, those with known
results and published trials are recorded on Table 1. Completed
trials were mostly industry sponsored (89%), controlled (75%),
phase 3/4 (76%), with a recruitment between 100 to 500 subjects
(42%), and evaluating unregistered drugs (62%). Overall, 41
different medical specialties were involved, being the most
prevalent, oncology (160), neurology (90), infectious diseases (59),
and cardiology (55). A total of 431 different chemical entities were
evaluated as experimental treatment. Median duration of all
completed clinical trials was 2?03 years (range 115 days–11?3
years).
Results were identified for 541 of the 785 completed trials. The
most frequent source of results were peer reviewed journals (380),
followed by final reports submitted to EC (225), online clinical
study results synopsis (148), and meeting abstracts (52) (figure 2).
For 314 trials only one source of results was located (65 study final
reports, 200 journal articles, 26 online final reports and 23
congress abstracts). One hundred and ninety had two sources of
results and for 37 completed trials we found three different sources
of results. Full text of results could not be accessed for 4/541
studies and 22/541 had null or partial analyses. Of these 22 trials,
9 corresponded to prematurely terminated studies, while for the
other 13 only preliminary reports could be identified. Analysis of
the 515 studies with full text results and complete analyses resulted
in 212 studies with positive results, 186 with negative results, and
117 with descriptive results.
Seventy nine of the 785 completed trials evaluated drugs in
indications already approved, while 222 evaluated registered drugs
in unapproved indications, and 484 investigated previously
unregistered investigational drugs. Analysis of experimental drug
labels upon completion of the trial revealed that for 245 of all
completed trials evaluating off label drug uses and unregistered
drugs, the investigated drug use had been approved by regulatory
authorities (34?7%).
Publication Rate
Publication rate in peer reviewed journals was 48?5% (380/785)
for all completed trials, and 21?3% for prematurely terminated
studies (23/108). In the phase 3 or 4 trials subgroup, publication
rate was 50?6% (304/601), and 56?8% (184/324) for trials with
drugs whose conditions of use were already approved or had been
approved by regulatory authorities after trial completion.
Publication rate was 84?9% for studies with positive results
(180/212) and 68?8% (128/186) for studies with negative results.
Sixty nine of the 117 studies with descriptive results were
published (59%) (Table 2). Trials with positive results were more
likely to be published than those with negative results, in the total
population of finished trials (OR=2?55; IC95: 1?56–4?15), in the
phase 3 or 4 trial subpopulation (OR=2?80; IC95: 1?62–4?84),
Figure 1. Flowchart of evaluated clinical trials.
doi:10.1371/journal.pone.0054583.g001
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and in the population of trials evaluating subsequently approved
drugs and indications (OR=4?28; IC95: 1?84–10?00).
Time to Publication
Mean follow-up time of trials since their completion was 4?24
years (IC95: 4?03–4?46) with a range of 8 days to 12?19 years.
Median survival time (MST) from study completion to
publication was 1081 days (2?96 years) (IC95: 2?68–3?24) for all
trials. Positive trials were published significantly earlier
(MST=2?09 years; IC95: 1?61–2?56) than negative
(MST=3?21 years; IC95: 2?69–3?74), and descriptive
(MST=3?75 years; IC95: 3?04–4?46) (p,0?001) (Figure 3).
Table 1. Characteristics of finished studies, studies with known results and published studies.
Finished studies (n =785) Studies with known results (n=537)2 Published studies (n =380)
Prematurely terminated 108 (13?8%) 50 (9?3%) 23 (6?1%)
Type of sponsorship
Industry 697 (88?8%) 487 (90?7%) 341 (89?7%)
Non-industry 88 (11?2%) 50 (9?3%) 39 (10?3%)
Phase of study
1/2 184 (23?4%) 126 (23?5%) 76 (20?0%)
3/4 601 (76?6%) 411 (76?5%) 304 (80?0%)
Study design
Controlled 590 (75?2%) 417 (77?7%) 315 (82?9%)
Uncontrolled 195 (24?8%) 120 (22?3%) 65 (17?1%)
Sample size1
Less than 100 187 (23?8%) 115 (21?4%) 72 (18?9%)
100 to 500 333 (42?4%) 228 (42?5%) 155 (40?8%)
500 to 1000 146 (18?6%) 106 (19?7%) 78 (20?5%)
More than 1000 100 (12?7%) 87 (16?2%) 75 (19?3%)
Conditions of use of study drug
Registered drugs. Approved use 79 (10?1%) 49 (9?1%) 34 (8?9%)
Registered drugs. Off label use 222 (28?3%) 162 (30?2%) 117 (30?8%)
Unregistered drugs 481 (61?7%) 326 (60?7%) 229 (60?3%)
1Trial sample size unknown for 19 studies.
24 trials with results located but unavailable for analysis.
doi:10.1371/journal.pone.0054583.t001
Figure 2. Flowchart of study results research.
doi:10.1371/journal.pone.0054583.g002
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After adjusting per sponsorship type, phase of study, sample size
and medical specialty, an association between study outcomes and
publication time exists, with a hazard ratio of 1?99 (IC95: 1?55–
2?55) favouring positive over negative studies (Table 3). These
results were consistent on the subsequent sub-analyses performed
on phase 3 and 4 trials (HR=2?11; IC95: 1?61–2?77), and trials
involving approved indications and drugs (HR=2?43; IC95:
1?56–3?79).
Non industry sponsorship, and a sample size larger than 1000
subjects were also associated with shorter publication times
(HR=1?93; IC95: 1?33–2?80 and HR=2?52; IC95: 1?67–3?81,
respectively). The association of a larger sample size and time to
publication was consistent in all three analyses, while the
sponsorship association was not present in the approved drug
trials subgroup.
Impact Factor
The 380 published trials were published in 125 different
journals. Journals with the highest number of published trials were
New England Journal of Medicine (47), Journal of Clinical
Oncology (38), The Lancet (23) and Annals of Oncology (12).
Table 2. Publication rates of completed trials with known results.
All trials (n= 515) Phase 3 and 4 trials(n= 402) Trials with approved drugs and uses (n=233)
Total Published Total Published Total Published
Positive results 212 180 (84?9%) 190 165 (86?8%) 132 120 (90?9%)
Negative results 186 128 (68?8%) 151 106 (70?2%) 50 35 (70?0%)
Results 117 69 (59?0%) 61 31 (50?8%) 51 27 (52?9%)
26 trials with null analysis or results not available were excluded (including 3 published studies).
doi:10.1371/journal.pone.0054583.t002
Figure 3. Kaplan Meier survival curves of time to publication sorted by study outcomes (positive, negative, descriptive).
doi:10.1371/journal.pone.0054583.g003
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Median (interquartile range[IQR]) impact factor (IF) for all 380
published articles was 6?448 (3?568–17?157). Comparison of IF
values according to study outcomes revealed no differences in
between positive (median: 6?308, IQR: 3?141–28?409) and
negative trials (median: 8?266, IQR: 4?135–17?157), while for
descriptive trials mean IF was significantly lower (median: 4?935,
IQR: 3?498–10?313).
In phase 3 and 4 trials, higher IF values were found for trials
with negative results, with statistically significant differences
between all groups, while in the subgroup of trials with approved
drugs, no differences were found (Table 4).
Discussion
The results of this long-term, extensive study, evidence that
available published clinical trial results do not match the originally
generated outcomes, since negative results are published signifi-
cantly less and later than positive results, compromising evidence
based medical decisions. Interestingly, no differences have been
found on impact factor of publications of clinical trials with
positive or negative results, which seems to indicate that overall,
statistical significance of results is not a major reason for rejection
of clinical trial articles by journal editors.
Clinical trial publication is not a clearly dichotomic process [1],
[18]. Results may appear in a number of different forms of
presentation, which include, but are not restricted to medical
journal articles. In order to assess publication bias, we considered
different sources of presentation of results, which include final
clinical study reports addressed to the EC, synopsis of results made
available online by the sponsors, meeting abstracts, and especially,
journal articles. However, a study has been classified as published
only when global results of the trial have appeared as an article in
a medical journal, since it has been considered that only original
articles contain public information sufficiently detailed to allow
decision making [19]. It should be noted that journal articles, in
contrast to data submitted online by sponsoring companies or
available as meeting abstracts, have a previous review process that
guarantees quality and completeness of the information provided.
A documented phenomenon [20–23] not foreseen in the original
design of this study was that comparison between publications and
original protocols revealed in some cases differences in main
outcomes presented in the journal article. Quantifying and
analyzing this phenomenon was beyond the scope of this study,
and in those cases, a decision was made to prioritize the main
outcome as presented in the article in order to classify study
results. Thus, in some cases, a trial classified as positive might have
been negative if the protocol main outcome had been taken into
consideration.
Out of the 785 completed clinical trials, the results of 244 (31%)
could not be identified by any of the means of results presentation
investigated in this study. Fifty eight of these 244 were prematurely
cancelled, but the other 186 were completed according to
protocol, which means there is a substantial amount of informa-
tion missing regarding clinical trials that were performed and
Table 3. Predictors of time to publication.
All trials (n= 785) Phase 3 and 4 trials (n = 601)
Trials with approved drugs and uses
(n =324)
HR (IC95) P HR (IC95) p HR (IC95) p
Negative outcome 1 1 1
Positive outcome 1?99 (1?55–2?55) ,0?001 2?11 (1?61–2?77 ) ,0?001 2?43 (1?56–3?79) ,0?001
Descriptive outcome 0?90 (0?64–1?27) 0?57 0?75 (0?49–1?15 ) 0?19 0?78 (0?44–1?37) 0?38
Industry-sponsored 1 1 1
Nonindustry-sponsored 1?93 (1?33–2?80) 0?001 1?90 (1?28–2?83) 0?001 1?18 (0?63–2?20) 0?61
Sample size ,100 1 1 1
Sample size 100 to 500 0?89 (0?64–1?24) 0?50 0?81 (0?54–1?21 ) 0?30 0?90 (0?48–1?69) 0?74
Sample size 500 to 1000 0?98 (0?67–1?43) 0?93 0?90 (0?58–1?39) 0?63 1?12 (0?56–2?25) 0?74
Sample size .1000 2?52 (1?67–3?81) ,0?001 2?37 (1?49–3?77) ,0?001 2?45 (1?18–5?10) 0?02
Phase 1/2 1 – – 1
Phase 3/4 1?00 (0?74–1?36) 0?98 – – 0?71 (0?38–1?31) 0?27
doi:10.1371/journal.pone.0054583.t003
Table 4. Impact factor of publications.
Study results Median (IQR) p
All trials
Positive (n = 180) 6?308 (3?141–28?409) 0?173(1)
Negative (n = 128) 8?266 (4?135–17?157)
Descriptive (n = 68) 4?935 (3?498–10?313) 0?012(2)
Global (n = 376) 6?448 (3?568–17?157)
Phase 3 or 4 trials
Positive (n = 165) 6?030 (3?082–22?933) 0?027(1)
Negative (n = 106) 9?863 (4?267–28?409)
Descriptive (n = 30) 4?206 (2?912–5?252) ,0?001(2)
Global (n = 303) 6?325 (3?164–17?157)
Trials with approved drugs and uses
Positive (n = 120) 5?839 (3?064–17?457) 0?896(1)
Negative (n = 35) 7?056 (2?704–17?157)
Descriptive (n = 27) 4?935 (2?970–17?157) 0?537(2)
Global (n = 184) 5?613 (2?979–17?157)
3 trials with null/partial/non available analysis and 1 trial published in a journal
not listed on 2008 impact factor index were excluded.
(1)Comparison between studies with positive and negative results.
(2)Comparison between studies with positive, negative and descriptive results.
doi:10.1371/journal.pone.0054583.t004
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completed. A possibility of mismatching and even misidentification
of publication exists [20–25], although we believe we have
partially overcome this problem by using multiple criteria to
match publications with protocols. Another potential weakness of
this study comes from the censoring date used. The follow up time
since study submission was decided in order to allow for the
maximum number of studies to be completed and published. Since
we are aware that these data might change overtime, a survival
study design was applied to analyze this data, in order to add
validity to our results. It should also be noted that investigator –
and more importantly- sponsor reasons for not dissemination of
study results – other than the direction of results- were not
investigated in this study.
Previous studies evidencing publication bias have been very
diverse in terms of research questions, design and study
characteristics, and thus have limitations in terms of validity.
The present study has used a single wide cohort of clinical trials
which were followed since their inception, and has quantified
publication bias through the fusion of results published on medical
journals and results obtained through other routes, including a
non-public cohort, less susceptible to biases, constituted by clinical
final reports submitted to the EC.
Our study provides clear evidence of the existence of
publication bias favoring positive result studies over negative.
Previous studies, performed in different areas of clinical research,
including basic experimental studies, observational studies, and
clinical trials, have shown the existence of a positive association
between publication rates and favorable outcomes [8–12].
Publication bias may be quantified not only through publication
rates, but also through the speed with which results are made
available. When time of publication depends on the nature of
results, this phenomenon is qualified as time lag bias [26], [27]. In
our study, mean survival time to publication has been over one
year shorter for positive studies than for negative studies. Previous
studies, using smaller cohorts of clinical trials, have confirmed an
association between study results over time to publication [9], [13].
However, the findings of these studies cannot be compared with
our results, due to the different criteria used to measure time to
publication. Given the high variability in study duration, we
considered more appropriate to measure time to publication as the
interval between date of study closure (end of follow-up) and date
of publication.
Studies with a descriptive hypothesis have shown lower
publication rates and longer times to publication, which is
indicative of a lesser priority applied to this type of studies in
comparison to those with a comparative hypothesis. However,
surprisingly, extent of publication and time lag bias has been
greater when analyzing only phase 3/4 trials and those whose
conditions of use have been approved after the trial, since this is a
population of trials with a major influence on clinical practice.
These results confirm the findings of a previous study evaluating
the rate of publication of 909 trials supporting new drugs approved
by the FDA and in which it was reported that rate of publication
was associated with significance of outcomes [28]. Undoubtedly,
the application of the FDA Amendments Act of 2007, which
mandates basic public results reporting for all trials supporting
FDA-approved drugs, will have an effect on this scenario in the
future. As other authors have pointed out [28], this information
will be publically available, but it is unknown whether -or how/
when- negative trials data will translate into journal article
publications.
Impact factor is an index based on the frequency with which a
journal article is cited on scientific publication, and is considered a
marker of journal quality [29]. There is a possibility of bias during
review process previous to publication, if the reasons for rejection
or acceptation are related to study results, independently of the
scientific quality of the study. Four studies that examined
manuscripts submitted to different journals concluded that
manuscript acceptation was not associated with the statistical
significance of the studies [30–33]. However, experimental cohort
studies on published trials seem to indicate otherwise [3], [14],
[15].
Our study has found no differences in impact factor of
publication of clinical trials with positive or negative results, while
for descriptive trials the values of impact factor have been
significantly lower. Moreover, in phase 3 and 4 trials, higher
impact factor values were found for trials with negative results.
This would seem to indicate that publication bias is set, not at the
moment of selection of articles by journal editors, but previously,
when the decision to submit or not manuscripts for publication is
taken, as other authors have stated [12], [34].
The design of a study of these characteristics, involving follow-
up of trials since their inception, requires a considerable amount of
time of execution, to allow for a sufficient time in order for the
trials to be completed and published, as is the case for this cohort
of studies, which started in 1997. Further research is needed to
evaluate the effect of the newly initiatives destined to increase
study results transparency, such as prospective registration of
clinical trials, open access to results policy, and improved trial
publication guidelines.
The results of this study point out to the fact that a change in
paradigm is needed when access to clinical trial results is
concerned. All actors implicated, investigators, regulatory author-
ities, journal editors, and especially, sponsoring companies, should
provide for means to guarantee and increase public availability of
unpublished results.
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